4593 Stock Overview Engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Add notePrice History & Performance
Summary of share price highs, lows and changes for Healios K.K Historical stock prices Current Share Price JP¥266.00 52 Week High JP¥267.00 52 Week Low JP¥114.00 Beta 0.94 1 Month Change 53.76% 3 Month Change 29.76% 1 Year Change 83.45% 3 Year Change -74.25% 5 Year Change -85.37% Change since IPO -84.24%
Recent News & Updates
Forecast to breakeven in 2027 Dec 31
Healios K.K. Announces Executive Changes Dec 19
Is Healios K.K (TSE:4593) Weighed On By Its Debt Load? Dec 05
Healios K.K. to Report Fiscal Year 2024 Results on Feb 14, 2025 Dec 03
Healios K.K. Announces Agreement with the FDA on Pivotal, Global Phase 3 "REVIVE-ARDS" Clinical Trial Sep 11
Price target increased by 17% to JP¥340 Sep 09 See more updates
Forecast to breakeven in 2027 Dec 31
Healios K.K. Announces Executive Changes Dec 19
Is Healios K.K (TSE:4593) Weighed On By Its Debt Load? Dec 05
Healios K.K. to Report Fiscal Year 2024 Results on Feb 14, 2025 Dec 03
Healios K.K. Announces Agreement with the FDA on Pivotal, Global Phase 3 "REVIVE-ARDS" Clinical Trial Sep 11
Price target increased by 17% to JP¥340 Sep 09
Healios K.K. to Report Q3, 2024 Results on Nov 13, 2024 Aug 27
Consensus EPS estimates upgraded to JP¥29.83 loss Jun 29
Healios K.K. to Report Q2, 2024 Results on Aug 13, 2024 Jun 06
Is Healios K.K (TSE:4593) Using Too Much Debt? May 31
First quarter 2024 earnings: EPS and revenues miss analyst expectations May 16
New major risk - Share price stability Apr 09 Healios K.K. (TSE:4593) completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC . Apr 05
Healios K.K. to Report Q1, 2024 Results on May 13, 2024 Mar 23
Consensus revenue estimates increase by 64% Mar 09
Consensus revenue estimates fall by 24% Feb 22
Consensus revenue estimates fall by 24% Feb 21
Consensus revenue estimates fall by 24% Feb 21
Consensus revenue estimates fall by 24% Feb 21
Consensus revenue estimates fall by 24% Feb 21
Full year 2023 earnings: EPS and revenues miss analyst expectations Feb 17
Healios K.K., Annual General Meeting, Mar 27, 2024 Feb 16
Healios K.K. and Procellcure Inc. Announce Start of Ards Clinical Trial in Japan Feb 03 Healios K.K. announced that it expects to receive ¥2.2600715 billion in funding Jan 26
Healios K.K. and Its Wholly Owned Subsidiary ProcellCure Inc. Announce Submission of ARDS Clinical Trial Notification in Japan Jan 19
Consensus EPS estimates upgraded to JP¥56.76 loss Dec 23
Healios K.K. to Report Fiscal Year 2023 Results on Feb 14, 2024 Dec 05
Third quarter 2023 earnings released: JP¥9.98 loss per share (vs JP¥12.31 loss in 3Q 2022) Nov 17
Consensus revenue estimates increase by 130% Oct 12
New minor risk - Market cap size Oct 11
HEALIOS K.K. Conducts the Treasure Study to Investigate the Safety and Efficacy of HLCM051 Oct 11
Healios K.K. to Report Q3, 2023 Results on Nov 14, 2023 Sep 24
HEALIO K.K. Provides its Innovative eNK Platform for A Novel Research Study on Metastatic Uveal Melanoma At Thomas Jefferson University in Philadelphia Sep 16
Price target increased by 11% to JP¥845 Aug 30
Second quarter 2023 earnings released: JP¥10.37 loss per share (vs JP¥32.62 loss in 2Q 2022) Aug 16
Healios K.K. Announces Use of 3D Bioreactor-Based Manufacturing Method Produced Product for ARDS Jul 06
HEALIOS K.K. and Sumitomo Pharma Co. Ltd. Announces Start of Phase 1/2 Study in RPE Tear Using RPE Cells Derived from Allogeneic iPS Cells (HLCR011) Jun 23
Healios K.K. to Report Q2, 2023 Results on Aug 14, 2023 Jun 11
Healios K.K. Announces Submission of Clinical Trial Notification for RPE Tail Using RPE Cells Derived from Allogeneic iPS Cells (HLCR011) May 25
First quarter 2023 earnings released: JP¥11.52 loss per share (vs JP¥26.47 loss in 1Q 2022) May 17
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Apr 01
Consensus EPS estimates upgraded to JP¥60.13 loss Mar 04
Price target decreased by 19% to JP¥762 Mar 03
Forecast to breakeven in 2025 Feb 18
Forecast to breakeven in 2025 Feb 15
Healios K.K. Announces Management Changes Jan 17
Forecast to breakeven in 2025 Jan 14
High number of new directors Dec 31
Healios K.K. to Report Fiscal Year 2022 Results on Feb 14, 2023 Dec 06
Third quarter 2022 earnings released: JP¥12.31 loss per share (vs JP¥34.86 loss in 3Q 2021) Nov 16 Healios K.K. announced that it has received ¥100.0316 million in funding from SATAKE Corporation Nov 08
HEALIOS Announces Results from the TREASURE Study Nov 03 Healios K.K. announced that it expects to receive ¥100.0316 million in funding from SATAKE Corporation Oct 19
Healios K.K. NK Cells Demonstrate Anti-Tumor Effect in Lung Cancer Patient-Derived Cancer Organoids Oct 12
Healios K.K. to Report Q3, 2022 Results on Nov 14, 2022 Oct 09
Consensus forecasts updated Aug 17
First half 2022 earnings released: JP¥59.11 loss per share (vs JP¥36.60 loss in 1H 2021) Aug 12
Healios K.K. to Report Q2, 2022 Results on Aug 10, 2022 May 30
Healios K.K. Reports Top-Line Results from Treasure Study for Ischemic Stroke May 21
First quarter 2022 earnings released: JP¥26.47 loss per share (vs JP¥19.92 loss in 1Q 2021) May 11
Price target decreased to JP¥2,760 Apr 27
Less than half of directors are independent Apr 27
Healios K.K. to Report Q1, 2022 Results on May 16, 2022 Apr 09
Price target decreased to JP¥2,760 Apr 07
Healios K.K. Announces Completion of 365 Days Post-Administration Follow Up for TREASURE Study for Patients with Ischemic Stroke Apr 05
Healios K.K. Provides Progress Update in Relation to Application for Approval for HLCM051 for ARDS Apr 04
Full year 2021 earnings released: JP¥93.36 loss per share (vs JP¥107 loss in FY 2020) Apr 02
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 17
Healios K.K., Annual General Meeting, Mar 25, 2022 Feb 16
Healios K.K. Announces Announcement of Change in Management Jan 31
Third quarter 2021 earnings released: JP¥34.78 loss per share (vs JP¥29.02 loss in 3Q 2020) Nov 15
HEALIOS K.K. Announces Positive Topline Results of MultiStem for Acute Respiratory Distress Syndrome in the ONE-BRIDGE Study Aug 08
First quarter 2021 earnings released: JP¥19.92 loss per share (vs JP¥29.02 loss in 1Q 2020) May 17
Healios K.K. to Report Q1, 2021 Results on May 14, 2021 Feb 28
Athersys, Inc. Announces Cooperation Agreement With HEALIOS K.K Feb 17
New 90-day low: JP¥1,562 Feb 15
Healios K.K. Announces Basic Business Agreement with Spline Corporation Regarding Sales of Pharmaceuticals Feb 06
New 90-day low: JP¥1,724 Jan 15
HEALIOS K.K. Conducts Two Clinical Trials Using Stem Cell Product Hlcm051*1 Jan 04
Healios K.K. to Report Fiscal Year 2020 Results on Jan 12, 2021 Dec 10
Healios K.K. to Report Q3, 2020 Results on Nov 13, 2020 Sep 03 Shareholder Returns 4593 JP Biotechs JP Market 7D 13.2% -0.08% 2.6% 1Y 83.4% 11.3% 8.4%
See full shareholder returns
Return vs Market: 4593 exceeded the JP Market which returned 8.4% over the past year.
Price Volatility Is 4593's price volatile compared to industry and market? 4593 volatility 4593 Average Weekly Movement 7.3% Biotechs Industry Average Movement 8.0% Market Average Movement 3.5% 10% most volatile stocks in JP Market 7.4% 10% least volatile stocks in JP Market 1.9%
Stable Share Price: 4593's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4593's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company develops HLCM051, which is preparing for phase 3 clinical trial, as well as preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is in phase 2/3 and phase 3 clinical trial to treat ischemic stroke; and HLCM051, which is in phase 2 clinical trial to treat trauma. It also develops HLCR011, which is in phase 1/2 clinical trial for the treatment of retinal pigmen epithelium and age-related macular degeneration; and HLCN061, which is in discovery and preclinical trial for treating solid tumors.
Show more Healios K.K. Fundamentals Summary How do Healios K.K's earnings and revenue compare to its market cap? 4593 fundamental statistics Market cap JP¥24.00b Earnings (TTM ) -JP¥6.22b Revenue (TTM ) JP¥549.00m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 4593 income statement (TTM ) Revenue JP¥549.00m Cost of Revenue JP¥98.00m Gross Profit JP¥451.00m Other Expenses JP¥6.67b Earnings -JP¥6.22b
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
Earnings per share (EPS) -68.97 Gross Margin 82.15% Net Profit Margin -1,133.33% Debt/Equity Ratio 117.8%
How did 4593 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/26 00:08 End of Day Share Price 2025/01/24 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Healios K.K. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Hidemaru Yamaguchi Citigroup Inc Akinori Ueda Goldman Sachs Stephen Barker Jefferies LLC
Show 6 more analysts